Pune, India, August 2018/MRFR Press Release/- Market Research Future has published a half-cooked research report on the global alagille syndrome market.
Alagille syndrome is a very rare genetic disease which is responsible for the failure of multiple body organ systems due to genetic changes. It causes a decrease in bile flow due to less bile duct formation and finally, it affects the liver and other organs. alagille syndrome is diagnosed in infancy or in early childhood. Till date, no treatment or medicine is available in the market to cure the alagille syndrome, but it can be controlled by multiple treatments. Increasing prevalence of genetic disorders, increase in a number of alagille syndrome cases and increase in healthcare expenditure are the major factors driving the growth of the global alagille syndrome market. According to the National Organization for Rare Disorders, 1 out of 30,000 live births suffers from the alagille syndrome.
The high costs associated with treatment and lack of awareness about the disease are likely to hamper the market growth during the forecast period.
The market in the Americas is expected to dominate the global Alagille syndrome market during the forecast period owing to the increasing prevalence of genetic diseases along with the government initiatives and well-established healthcare sector in the region. According to the US national library of medicine, approximately 30 million people in the United States are living with rare diseases. This equates to 1 in 10 Americans or 10% of the U.S. population.
The European market is expected to be the second-largest market due to government funding and support to the healthcare sector, coupled with increasing research and development and increasing awareness about organ transplantation. According to Eurotransplant in the year 2017, around 2,900 patients were on the waiting list for a liver transplant and out of 2,900 more than 1,600 received the organ transplant within the year. Moreover, the market in Asia-Pacific is expected to show the fastest growth during the forecast period owing to technological development, increasing awareness and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global alagille syndrome market due to the undeveloped healthcare sector.
Get access to full summary @: https://www.marketresearchfuture.com/reports/alagille-syndrome-market-6324
The global alagille syndrome market has been segmented on the basis of symptom, diagnosis, treatment, and end-user.
On the basis of symptom, the market has been classified as liver problems, nutrition problems, heart problems, distinctive facial features, neurologic problems and others.
The diagnosis segment has been further divided into blood test, urinalysis, x-ray imaging, cardiology exam, slit-lamp exam, liver biopsy, genetic testing, prenatal DNA testing and others.
The Treatment segment has been divided into medication and biliary diversion procedures. medication segment has been further divided into ursodeoxycholic acid, cholestyramine, rifampin, naltrexone, antihistamines, and hydroxyzine. Moreover. biliary diversion procedures have been further segmented into vitamin supplements, liver transplantation, kidney surgery, heart surgery and others.
The market, by end-user, has been segmented into hospitals and clinics, diagnostic centers, others.
Some of the key players in the global alagille syndrome market are Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergan Plc, Lannett, Albireo Pharma, Inc., AstraZeneca PLC, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Merck & Co., Inc